Skip to main content

Clinical results in cachexia therapeutics.

Publication ,  Journal Article
Crawford, J
Published in: Curr Opin Clin Nutr Metab Care
May 2016

PURPOSE OF REVIEW: This article highlights recent developments in the area of cancer cachexia and therapeutic interventions. RECENT FINDINGS: Therapeutic interventions in cancer cachexia have been guided by clinical studies focused on the central role of muscle and the increased use of CT imaging to measure the impact of skeletal muscle loss on clinical outcomes. At the translational level, a number of different model systems have emphasized the importance of blockade of tumor-induced inflammation and its potential impact on reversing the cachexia phenotype, including FN14, a receptor in the TNF pathway, as well as the parathyroid hormone-related protein. Clinical studies continue to demonstrate the importance of nutrition and exercise as part of a multimodality approach. Although a number of promising agents are being evaluated, both enobosarm, a selected androgen receptor modulator, and anamorelin, a ghrelin agonist have completed phase III trials. Both agents have shown significant impact on reversal of skeletal muscle loss, but inconsistent effect on physical function improvement. Anamorelin also has a positive effect on appetite and weight gain. SUMMARY: Further analysis of these studies, along with regulatory guidance, will be critical in the further development of these and other promising agents in the clinical management of patients with cancer cachexia.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Curr Opin Clin Nutr Metab Care

DOI

EISSN

1473-6519

Publication Date

May 2016

Volume

19

Issue

3

Start / End Page

199 / 204

Location

England

Related Subject Headings

  • Wasting Syndrome
  • Receptors, Ghrelin
  • Receptors, Androgen
  • Oligopeptides
  • Nutrition & Dietetics
  • Neoplasms
  • Muscle, Skeletal
  • Ligands
  • Hydrazines
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Crawford, J. (2016). Clinical results in cachexia therapeutics. Curr Opin Clin Nutr Metab Care, 19(3), 199–204. https://doi.org/10.1097/MCO.0000000000000274
Crawford, Jeffrey. “Clinical results in cachexia therapeutics.Curr Opin Clin Nutr Metab Care 19, no. 3 (May 2016): 199–204. https://doi.org/10.1097/MCO.0000000000000274.
Crawford J. Clinical results in cachexia therapeutics. Curr Opin Clin Nutr Metab Care. 2016 May;19(3):199–204.
Crawford, Jeffrey. “Clinical results in cachexia therapeutics.Curr Opin Clin Nutr Metab Care, vol. 19, no. 3, May 2016, pp. 199–204. Pubmed, doi:10.1097/MCO.0000000000000274.
Crawford J. Clinical results in cachexia therapeutics. Curr Opin Clin Nutr Metab Care. 2016 May;19(3):199–204.

Published In

Curr Opin Clin Nutr Metab Care

DOI

EISSN

1473-6519

Publication Date

May 2016

Volume

19

Issue

3

Start / End Page

199 / 204

Location

England

Related Subject Headings

  • Wasting Syndrome
  • Receptors, Ghrelin
  • Receptors, Androgen
  • Oligopeptides
  • Nutrition & Dietetics
  • Neoplasms
  • Muscle, Skeletal
  • Ligands
  • Hydrazines
  • Humans